Dapagliflozin Acute Heart Failure Trial - AstraZeneca
Summary
The National Library of Medicine posted a new clinical trial registration on ClinicalTrials.gov for a Phase 4 study sponsored by AstraZeneca evaluating dapagliflozin in acute heart failure patients. The trial (NCT07499831) is currently recruiting participants at multiple study locations.
What changed
AstraZeneca registered a new clinical trial (NCT07499831) on ClinicalTrials.gov to evaluate dapagliflozin, an SGLT2 inhibitor, for the treatment of acute heart failure. The study is classified as Phase 4 and is currently recruiting. This registration satisfies requirements under FDAAA 801 for applicable clinical trials to be registered within 21 days of enrollment initiation.
Pharmaceutical companies and clinical investigators should verify their active trials are properly registered and updated on ClinicalTrials.gov. Trial sponsors must ensure enrollment status is accurately maintained and results are submitted within 12 months of trial completion for applicable studies.
Source document (simplified)
Show glossary
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.